The US Court of Appeals for the Federal Circuit this week revived a stent patent infringement suit brought by Medinol against Cordis and its former parent company Johnson & Johnson (NYSE:JNJ). The suit, originally filed in 2013, claimed that Cordis infringed on Medinol stent patents filed between 1999 and 2005. The case was vacated in 2014 […]
Cordis, Medinol tout first commercial implants of Elunir drug-eluting stent in U.S.
Cordis and Medinol announced today that the first commercial uses of the Elunir drug-eluting stent in the U.S. were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute in Atlanta. The Elunir stent, developed by Medinol and distributed by Cordis, features a metallic spring tip and the narrowest strut width of any stent on […]
Cordis, Medinol win FDA nod for Elunir drug-eluting stent
Cordis and Medinol announced today that the FDA approved its Elunir drug-eluting stent for the treatment of patients with narrowing or blocked coronary arteries. The stent, designed by Medinol and distributed exclusively by Cordis in the U.S., features a novel metallic spring tip and the narrowest strut width of any stent on the market in the U.S., according […]
Cordis inks exclusive distribution deal for Medinol’s coronary stent portfolio in US
Cordis has inked an exclusive distribution deal to sell Medinol‘s coronary stents in the U.S., the company reported, adding a cobalt-chromium bare-metal stent and a drug-eluting stent to its portfolio. According to the deal, Cordis plans to start selling Medinol’s NIRxcell BMS immediately and will exclusively distribute the company’s EluNir drug-eluting stent if it wins FDA approval. […]
Medinol wins CE Mark for EluNir drug-eluting coronary stent system
Medinol said today that it won CE Mark clearance for its EluNir drug-eluting stent – a device designed with a low metal footprint and a elastomeric coating. In one 958-patient clinical study, the coronary stent had a 12-month target lesion failure rate of 5.4% and a 0% rate of late stent thrombosis, proving non-inferior to the […]
Supreme Court remands medical device patent cases
The U.S. Supreme Court sent back several appeals to the federal circuit this week, including 1 relating to Johnson & Johnson‘s (NYSE:JNJ) stent patent fight with Medinol, in light of a recent vote regarding the use of laches in patent infringement cases. Defendants use laches to declare that a plaintiff unreasonably delayed in bringing a claim […]
Japan OKs Medinol stent trial
Medinol said yesterday that Japanese regulators approved a clinical trial of its Elunir drug-eluting stent that it plans to add to an ongoing U.S. trial of the device. The thin-strut, ridaforolimus-eluting Elunir stent (previously known as Bionir) features an elastomeric coating that’s designed to be more flexible than prior-generation polymer coatings. Last month, Medinol presented 1-year […]
EuroPCR 2016 Update: TAVR innovations, FFR systems in the spotlight
UPDATED May 20, 2016, with more results out of Paris. St. Jude Medical (NYSE:STJ) announced it won CE Mark approval in the European Union for its PressureWire X Guidewire fractional flow reserve measurement system and is launching the product in Europe. The company announced the launch and clearance at the EuroPCR meeting in Paris this week. […]
Medinol launches trial for NIRxcell stent
Medinol said it enrolled the 1st U.S. patient in a post-market study of its bare-metal NIRxcell stent, which has been on the U.S. market since January 2015. Tel Aviv-based Medinol said the NIRxcell stent is a 5th-generation stent using its WiZeCell design and the Flexx2 spring-tip delivery catheter. The device 1st won pre-market approval from the FDA in December […]
Johnson & Johnson logs win in Cordis-Medinol stent patent spat
Abbott claims win over Medinol in Dutch stent patent fight
MassDevice Network
@MassDevice
LinkedIn
YouTube